Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial-mesenchymal transition

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 1, 2014, Pages 49-58

  He, Lu ^a   Zhou, Xinke ^a   Qu, Chen ^b   Hu, Lijuan ^a   Tang, Yunqiang ^a   Zhang, Qiong ^a   Liang, Min ^a   Hong, Jian ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Biomarker; Hepatocellular carcinoma; Invasion; Musashi (MSI); Prognosis

Indexed keywords

BIOLOGICAL MARKER; MSI2 PROTEIN, HUMAN; RNA BINDING PROTEIN; SMALL INTERFERING RNA;

ARTICLE; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; GENETICS; HUMAN; INVASION; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MUSASHI (MSI); PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; TUMOR INVASION;

BIOMARKER; HEPATOCELLULAR CARCINOMA; INVASION; MUSASHI (MSI); PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PROGNOSIS; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS;

EID: 84891371359     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12158     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA. 2011; 61: 69-90.
2. Kuper H, Ye W, Broome U, et al. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology. 2001; 34: 714-8.
3. Avila MA, Berasain C, Sangro B, et al. New therapies for hepatocellular carcinoma. Oncogene. 2006; 25: 3866-84.
4. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005; 97: 1532-8.
5. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006; 23: 1535-47.
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. New Engl J Med. 2008; 359: 378-90.
7. Treiber G. Systemic treatment of hepatocellular carcinoma. Dig Dis (Basel, Switzerland). 2001; 19: 311-23.
8. Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006; 243: 229-35.
9. de Andres-Aguayo L, Varas F, Graf T. Musashi 2 in hematopoiesis. Curr Opin Hematol. 2012; 19: 268-72.
10. Glazer RI, Wang XY, Yuan H, et al. Musashi1: a stem cell marker no longer in search of a function. Cell Cycle. 2008; 7: 2635-9.
11. Sakakibara S, Nakamura Y, Satoh H, et al. RNA-binding protein Musashi2: developmentally regulated expression in neural precursor cells and subpopulations of neurons in mammalian CNS. J Neurosci. 2001; 21: 8091-107.
12. Okano H, Imai T, Okabe M. Musashi: a translational regulator of cell fate. J Cell Sci. 2002; 115: 1355-9.
13. Imai T, Tokunaga A, Yoshida T, et al. The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA. Mol Cell Biol. 2001; 21: 3888-900.
14. Nikpour P, Baygi ME, Steinhoff C, et al. The RNA binding protein Musashi1 regulates apoptosis, gene expression and stress granule formation in urothelial carcinoma cells. J Cell Mol Med. 2011; 15: 1210-24.
15. Wang XY, Penalva LO, Yuan H, et al. Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer. 2010; 9: 221.
16. Sureban SM, May R, George RJ, et al. Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. Gastroenterology. 2008; 134: 1448-58.
17. Li D, Peng X, Yan D, et al. Msi-1 is a predictor of survival and a novel therapeutic target in colon cancer. Ann Surg Oncol. 2011; 18: 2074-83.
18. Liu DC, Yang ZL, Jiang S. Identification of musashi-1 and ALDH1 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Cancer Biomarkers. 2010; 8: 113-21.
19. Ito T, Kwon HY, Zimdahl B, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature. 2010; 466: 765-8.
20. Byers RJ, Currie T, Tholouli E, et al. MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia. Blood. 2011; 118: 2857-67.
21. Hong J, Hu K, Yuan Y, et al. CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J Clin Invest. 2012; 122: 2165-75.
22. Xia L, Huang W, Tian D, et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology. 2013; 57: 610-24.
23. Tanaka S, Shiraha H, Nakanishi Y, et al. Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma. Int J Cancer. 2012; 131: 2537-46.
24. Zhou ZJ, Dai Z, Zhou SL, et al. Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma. Int J Cancer. 2013; 132: 1080-9.
25. Ma W, Wong CC, Tung EK, et al. RhoE is frequently down-regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho-kinase/myosin phosphatase target pathway. Hepatology. 2013; 57: 152-61.
26. Arias AM. Epithelial mesenchymal interactions in cancer and development. Cell. 2001; 105: 425-31.
27. Wuebben EL, Mallanna SK, Cox JL, et al. Musashi2 is required for the self-renewal and pluripotency of embryonic stem cells. PLoS ONE. 2012; 7: e34827.
28. Good P, Yoda A, Sakakibara S, et al. The human Musashi homolog 1 (MSI1) gene encoding the homologue of Musashi/Nrp-1, a neural RNA-binding protein putatively expressed in CNS stem cells and neural progenitor cells. Genomics. 1998; 52: 382-4.
29. Sakakibara S, Nakamura Y, Yoshida T, et al. RNA-binding protein Musashi family: roles for CNS stem cells and a subpopulation of ependymal cells revealed by targeted disruption and antisense ablation. Proc Natl Acad Sci USA. 2002; 99: 15194-9.
30. Kharas MG, Lengner CJ, Al-Shahrour F, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010; 16: 903-8.
31. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2: 442-54.
32. Zhang Q, Bai X, Chen W, et al. Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis. 2013; 34: 962-73.
33. Griner LN, Reuther GW. Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway. Cancer Biol Ther. 2010; 10: 979-82.
34. Spana EP, Doe CQ. Numb antagonizes Notch signaling to specify sibling neuron cell fates. Neuron. 1996; 17: 21-6.
35. Wakamatsu Y, Maynard TM, Jones SU, et al. NUMB localizes in the basal cortex of mitotic avian neuroepithelial cells and modulates neuronal differentiation by binding to NOTCH-1. Neuron. 1999; 23: 71-81.
36. Justice N, Roegiers F, Jan LY, et al. Lethal giant larvae acts together with numb in notch inhibition and cell fate specification in the Drosophila adult sensory organ precursor lineage. Curr Biol. 2003; 13: 778-83.